Gordon Dunn - 23 Dec 2024 Form 4 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Role
Chief Financial Officer
Signature
/s/ Gordon Dunn
Issuer symbol
QNRX
Transactions as of
23 Dec 2024
Net transactions value
+$54,999
Form type
4
Filing time
27 Dec 2024, 17:16:15 UTC
Previous filing
10 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QNRX Ordinary Shares Purchase $54,999 +122,221 +424% $0.4500 151,077 23 Dec 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNRX Series F Warrants (right to buy) Purchase +122,221 122,221 23 Dec 2024 ADS 122,221 $0.4500 Direct F2, F3
transaction QNRX Series G Warrants (right to buy) Purchase +122,221 122,221 23 Dec 2024 ADS 122,221 $0.4500 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.
F2 Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."
F3 The Warrants were exercisable immediately, subject to a beneficial ownership cap.